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Abstract 
Galectin-3 is a versatile protein orchestrating several physiological and pathophysiological processes 
in the human body. In the last decade, considerable interest in galectin-3 has emerged because of its 
potential role as a biotarget. Galectin-3 is differentially expressed depending on the tissue type, 
however its expression can be induced under conditions of tissue injury or stress. Galectin-3 
overexpression and secretion is associated with several diseases and is extensively studied in the 
context of fibrosis, heart failure, atherosclerosis and diabetes mellitus. Monomeric (extracellular) 
galectin-3 usually undergoes further “activation” which significantly broadens the spectrum of 
biological activity mainly by modifying its carbohydrate-binding properties. Self-interactions of this 
protein appear to play a crucial role in regulating the extracellular activities of this protein, however 
there is limited and controversial data on the mechanisms involved. We therefore summarize 
(recent) literature in this area and describe galectin-3 from a binding perspective providing novel 
insights into mechanisms by which galectin-3 is known to be “activated” and how such activation 
may be regulated in pathophysiological scenarios. 
Key words: Galectin-3; fibrosis; extracellular matrix; heart failure; renal disease; cardiovascular disease; 
interaction; cell-cell adhesion; carbohydrate binding domain  
Introduction 
Lectins are carbohydrate-binding proteins found 
in plants and animals that are specific for sugar 
moieties, and were initially defined as “sugar-binding 
proteins of non-immune origin that have the ability to 
agglutinate cells and precipitate glycoconjugates” [1]. 
Galectins belong to the family of animal-lectins and 
are a group of water soluble, non-glycosylated 
globular proteins that can interact with carbohydrates 
in a divalent cation-independent manner [2]. Two 
characteristic properties distinguish them from other 
animal-lectins: affinity for ß-galactoside derivatives 
and consensus amino-acid sequences [3,4]. Galectins 
are synthesized in the cytoplasm and function in both 
nuclear and cytoplasmic compartments. They are also 
secreted to the outer plasma membrane and the 
extracellular matrix (ECM), and are present in the 
circulation. Fifteen different galectins have been 
identified and characterized in humans, and are 
classified into three groups: proto-, chimera-, and 
tandem-repeat types based on their structure. The 
biological significance of galectins is paramount due 
to their vital role in several developmental and 
defence processes. The role of galectins as decipherers 
of glycocode has also been acknowledged for more 
than twenty years [5].  
As the only chimeric galectin member of the 
vertebrate family, galectin-3 has a very interesting 









sequence similarity to B-cell lymphoma-2 (Bcl-2) 
protein and is the only galectin containing a 
C-terminal anti-death NWGR motif [6]. Galectin-3 
orchestrates several physiological processes and has 
also been identified as a “culprit-molecule” in the 
pathogenesis of various diseases, especially fibrosis, 
cardiovascular disease and cancer.  
In this review, we summarize the function of 
galectin-3 in physiology and focus on its role in 
pathophysiological scenarios involving fibrosis, heart 
failure (HF), atherosclerosis and diabetes mellitus 
(DM). As galectin-3 is an emerging biotarget, we also 
describe its structure from a binding perspective 
paying special attention to the carbohydrate- 
recognition domain (CRD). Monomeric (extracellular) 
galectin-3 usually undergoes further “activation” 
which significantly broadens the spectrum of 
biological activity of this protein. However, precise 
knowledge in this direction is inadequate and the 
main aim of this article is to provide a deeper insight 
into mechanisms by which galectin-3 is known to be 
“activated”, and how such “activation” may be 
regulated in pathophysiological scenarios. 
Galectin-3: One Protein With Different 
Names 
Galectin-3 was previously known by several 
names including Mac-2 antigen [7], IgE-binding 
protein [8], L-29 [9,10] and CBP30 [11]. Galectin-3 was 
first identified by Ho and Springer as a macrophage 
sub-population specific marker (Mac-2 antigen) that 
was distributed in the cytosol, extracellular medium 
and also in membrane fractions of these cells [7]. 
Galectin-3 was also independently described as 
IgE-binding protein (eBP) [12], and analysis of eBP 
revealed two important constituent domains: CRD 
and amino domain carrying potential recognition 
sites for collagenase cleavage (N-terminal) [8]. 
Interactions of L-29 (galectin-3) with laminin and 
requirement of N-terminal in positive co-operative 
binding to laminin and other glycoconjugates were 
reported by Massa et al. [9], while in experiments 
involving baby hamster kidney cell extracts, the name 
carbohydrate binding protein-30 (CBP30) was 
frequently used (Figure 1) [11].  
LGALS3: The Galectin-3 Gene And Its 
Regulation 
LGALS3 is the single gene coding for galectin-3 
in the human genome and is situated on chromosome 
14, locus q21-22, and is composed of six exons and 
five introns spanning about 17 kilobases. Promoter 
methylation status of LGALS3, and elements such as 
CRE motifs, nuclear factor- κB (NF-κB) like sites and 
GC boxes located within the galectin-3 promoter 
regulate galectin-3 expression [13]. Galectin-3 also 
contains a special regulatory element called galig 
(galectin-3 internal gene) located within the second 
intron of LGALS3 gene [14]. The transcripts of 
galectin-3 and the internal promoter galig share 
common coding sequences but use alternative reading 
frames. Galig is a cell death gene coding for two 
proteins: a cytoplasmic protein, cytogaligin and a 
mitochondrial protein, mitogaligin. The interaction of 
mitogaligin with cardiolipin is believed to disrupt the 
mitochondrial membrane, and cell death induced by 
galig can be opposed by overexpression of myeloid 
cell leukaemia sequence 1 protein (MCL-1), which 
belongs to the anti-apoptotic Bcl-2 family [15]. 
Galectin-3 transcription can also be repressed by 
proteins such as Krüppel-like factor 3 (KLF-3), which 
belongs to the family of zinc finger transcription 
factors [16], or up-regulated by other transcription 




Figure 1: Galectin-3 was previously known by several names including Mac-2 
antigen, IgE-binding protein, carbohydrate-binding protein and L-29. Although 
the historical nomenclature is obsolete, it highlights the various fields in which 
galectin-3 research has evolved.  
 
Temporospatial Expression Of Galectin-3 Is 
Variable And Complex 
In adults, galectin-3 is ubiquitously distributed 
in hematopoietic tissue, thymus, lymph nodes, skin, 
respiratory tract, digestive tract, reproductive tract 
and urinary tract [18,19], and baseline galectin-3 
expression varies depending on tissue-type and 
tissue-maturity (Figure 2) [20]. Even within a tissue, 
different cell types express galectin-3 differentially: 





within the hematopoietic tissue, monocytes express 
galectin-3, and a higher amount is expressed in 
macrophages [18,21]. However, galectin-3 is virtually 
undetectable in human peripheral blood lymphocytes 
[6,22]. 
Although baseline galectin-3 expression is 
variable in different tissues, its expression is 
inducible. For instance, healthy cardiac tissue has a 
very low baseline galectin-3 expression, but during 
cardiac injury its expression is rapidly induced. 
Galectin-3 up-regulation plays a crucial role in the 
initial phases of tissue repair; however, sustained 
over-expression results in fibrosis of the heart [23,24]. 
Increased galectin-3 expression can also be induced in 
other tissues after injury, and this is significantly 




Figure 2: Western blot analysis of different tissues, adapted from Kim et al 
[20]. This figure illustrates the variability of galectin-3 in different murine tissues 
with the highest expression in lung, spleen, stomach, colon, uterus and ovary. 
While liver, kidney and adrenal gland display a moderate galectin-3 expression, 
baseline expression in the heart, pancreas and ileum is very low. 
 
Secretion and Translocation of Galectin-3  
Galectin-3 bypasses the classical “endoplasmic 
reticulum-Golgi apparatus” pathway [28] and is 
secreted via a non-classical mechanism. Although 
many factors are known to influence galectin-3 
secretion, e.g., heat shock, calcium ionophores, 
acylation and phosphorylation [29–31], the exact 
mechanisms remain to be elucidated. Intracellularly, 
phosphorylation and importin-mediated mechanisms 
appear to be involved in nucleo-cytoplasmic shuttling 
of galectin-3 [32–35], while synexin-mediated 
mechanisms are indicated in galectin-3 translocation 
to the mitochondria [36].  
Intracellular Galectin-3 
Galectin-3 interacts with various ligands within 
the cell to elicit several biological processes. Potential 
intracellular binding partners include anti-apoptotic 
molecules such as Bcl-2 [6], and signalling molecules 
such as Gemin4 [37] and ß-catenin [38]. Intracellular 
binding usually occurs via protein-protein 
interactions utilizing either N-terminal or CRD 
without involving sugar moieties, i.e., no 
protein-sugar interactions. However, in in vitro 
experiments, certain protein-to-protein interactions 
(e.g., galectin-3-Bcl-2 interaction, galectin-3-ß-catenin 
interaction) can also be inhibited by lactose [6,38]; this 
could be explained by the involvement of CRD in 
protein-protein interactions or conformational 
changes induced by lactose.  
Physiological Functions 
Intracellular galectin-3 has several biological 
functions related to growth and development such as 
implantation of the embryo [39] and renal 
morphogenesis [40,41]. Increased galectin-3 
expression is also found in the notochord, cartilage 
and bone during development [42], and appears to 
play a regulatory role in cellular fusion (e.g., 
osteoclast differentiation) [43], and cellular longevity 
(e.g., chondrocyte survival) [44,45]. However, most of 
this knowledge is obtained from murine experimental 
models.  
Pathophysiological functions 
Sustained galectin-3 expression, e.g., after tissue 
injury, could result in organ fibrosis. In vitro studies 
demonstrate that galectin-3-mediated fibrosis could 
be due to galectin-3 overexpression in several cell 
types: when murine and human hepatic stellate cells 
(HSCs) were activated by culturing on tissue culture 
plastic, a significant up-regulation of intracellular 
galectin-3 was observed. However, protein expression 
of α-smooth muscle actin (α-SMA, marker of HSC 
activation) in galectin-3-/- HSCs was insignificant 
compared to wild type (WT) HSCs [25]. This was also 
validated in an in vivo hepatic fibrosis model: liver 
sections from animals exposed to chronic chemical 
injury with CCl4 (8 weeks) displayed an intense signal 
for galectin-3, while controls expressed virtually no 
galectin-3. Furthermore, galectin-3 knockout (KO) 
mice treated with CCl4 also displayed a very low 
amount of collagen and α-SMA in hepatic tissue, 
while the WT mice demonstrated a significant 
increase in expression of these proteins [25]. 
Galectin-3 overexpression is also a characteristic 
feature of “profibrotic” M2 macrophages: naïve 
macrophages stimulated with interleukin-4 (IL-4) and 
IL-13 express higher levels of galectin-3, together with 





other markers of collagen turnover such as mannose 
receptors [46]. Although intracellular galectin-3 levels 
correlate with tissue repair [47,48] and subside over 
time, uncontrolled galectin-3 expression could result 
in sustained myofibroblast and macrophage 
activation leading to tissue fibrosis, possibly through 
intracellular and also extracellular signalling 
pathways.  
Intracellular galectin-3 levels are also known to 
affect the inflammatory response through various 
mechanisms [49]. However, limited data exist 
regarding the function of intracellular galectin-3 in 
neutrophil apoptosis. A recent study performed in a 
galectin-3 KO mouse model indicates that there is 
reduced apoptosis of neutrophils and also reduced 
neutrophil clearance by macrophages [50], suggesting 
that galectin-3 might be an important player in 
resolving the “neutrophil-phase” of inflammation. It 
is speculated that when exported to the neutrophil 
surface, galectin-3 could act as an opsonin and initiate 
clearance by promoting macrophage efferocytosis 
[51]. Macrophage galectin-3 expression also appears 
to have a crucial role in phagocytosis of apoptotic 
bodies [52].  
Recent studies also suggest that intracellular 
galectin-3 could have a greater role in the 
pathophysiology of DM type 1 by inducing β-cell 
apoptosis: β-cells from galectin-3 KO mice were 
resistant to inflammation-induced cell death by 
counteracting mitochondrial apoptotic pathways [53]. 
This is in contrast to previous research that 
demonstrated that intracellular galectin-3 supresses 
mitochondrial apoptotic pathways by preserving 
mitochondrial integrity [36]. 
In summary, the final outcome of the 
fibro-inflammatory response is determined by a 
dynamic balance between neutrophil apoptosis, 
macrophage and T-cell responses, fibroblast 
activation and myofibroblast persistence, and 
intracellular galectin-3 seems to be involved in many 
of these responses (Figure 3). However, our current 
understanding of galectin-3-mediated apoptotic 
mechanisms is limited and further studies are 
warranted to characterize the role of intracellular 
galectin-3 in apoptosis of different cell types, 
especially in immune-cells and collagen-producing 
cells. 
Extracellular Galectin-3  
Galectin-3 can be secreted to the cell surface 
where it binds to glycan-rich molecules in cell-surface 
glycoproteins and glycolipids. When exported to the 
ECM, it interacts with various 
glycosylated matricellular binding 
partners such as laminin, tenascin 
and fibronectin [54–56]. 
Extracellular galectin-3-binding 
usually occurs through protein- 
carbohydrate interactions, orches-
trated by the galectin-3 CRD; this 
results in lectin-saccharide bonds, 
typically inhibited by lactose [57]. 
Physiological functions 
Extracellular galectin-3 plays 
an important role in embryo-
genesis, growth and development, 
and also in maintaining homeos-
tasis [58,59]. For instance, CD98 
heavy chain is a glycosylated 
transmembrane protein expressed 
in developing human trophoblasts. 
In in vitro conditions, galectin-3 
associates with CD98 heavy-chain, 
possibly through lectin-glycan 
interactions, and facilitates 
placental (BeWo) cell fusion [58]; 
blocking galectin-3 CRD with 
lactose reduces cell fusion in these 
cells. Extracellular galectin-3 also 
appears to be an indispensable 
 
 
Figure 3: The role of galectin-3 in inflammation is ambiguous. Some studies suggest that apoptosis of 
neutrophils and their clearance by macrophages is reduced in galectin-3 KO mouse models. However, further 
research needs to be conducted as increased intracellular galectin-3 levels are usually associated with cellular 
longevity. The role of galectin-3 in fibrosis is well-established, and increased galectin-3 levels contribute to 
(myo)fibroblast activation through a TGF-β independent pathway and also through a TGF-β dependent 
pathway. Syndecans also play an important role, especially by affecting profibrotic signalling in cardiac 
fibroblasts, and possibly also by interacting with galectin-3. Furthermore, galectin-3 can also affect the fibrotic 
pathway by inducing alternative (M2) activation in macrophages. KO: knockout; TGF-β: transforming growth 
factor β 





player in cartilage and bone-matrix remodelling in 
and around the period of endochondral ossification 
[60]. Furthermore, association of extracellular 
galectin-3 with glycoproteins such as von Willebrand 
factor (vWF) [61], factor VIII [62] and hensin is 
believed to regulate homeostatic mechanisms, i.e., 
galectin-3-vWF interaction modulates thrombus 
formation and galectin-3-hensin interaction is shown 
to promote hensin oligomerization, which is 
considered to be essential for renal adaptation during 
metabolic acidosis [63].  
Interaction of galectin-3 with heavily 
glycosylated CD13 has been shown to aggregate 
monocytes and this process can be inhibited by lactose 
and anti-galectin-3 antibodies [64]; galectin-3 binding 
to other glycosylated partners such as CD98 has also 
been reported, and this mechanism is indicated in 
alternative activation of macrophages during wound 
healing [46]. Extracellular galectin-3 is also believed to 
facilitate monocyte migration by functioning as a 
chemotactic factor [65]. However, many of these 
extracellular functions were demonstrated by using 
recombinant protein added to cultured cells; whether 
these represent functions of endogenous galectin-3 
remains to be established.  
Extracellular galectin-3 also acts as an interpreter 
of glycocodes [5]. The sugar molecules from 
glycoproteins and glycolipids form the glycocalyx; 
unlike codes encrypted in amino-acids and 
nucleotides, these glycocodes (saccharides) are highly 
heterogeneous secondary gene products escaping 
direct control of genes. Due to the structural 
variability and complexity of carbohydrates, 
glycocodes carry a substantial amount of information 
and are able to influence a broad spectrum of 
biological activities by regulating various cellular 
processes [66]. They are also hypothesised to 
influence cell-survival by regulating entry of 
biological agents such as T-lymphocytes and viruses 
[67–69].  
Pathophysiological functions 
Galectin-3 is a “culprit” protein associated with 
several diseases. Herein, we focus on the role of 
extracellular galectin-3 in the pathogenesis of fibrosis, 
HF, atherosclerosis and DM type 2.  
Organ Fibrosis 
Genetic disruption of galectin-3 reduces or 
abolishes the development of fibrosis in various 
organs, e.g., heart, vessels, lung, liver and kidney 
[24–27,70,71]. Although profibrotic properties of 
galectin-3 can be studied using genetic KO models, it 
is not possible to conclude if it is intracellular or 
extracellular blockade (or both) that has resulted in 
reduction or loss of fibrosis. Other methods by which 
fibrotic effects of extracellular galectin-3 can be 
characterized is by adding recombinant galectin-3 to 
cells in in vitro experiments or through in vivo 
experiments involving pharmacological galectin-3 
blockade; several existing galectin-3 inhibitors appear 
to reduce fibrosis by acting extracellularly and can 
therefore be utilized to understand galectin-3 function 
at the cellular membrane and in the extracellular 
matrix.  
There are various mechanisms by which 
extracellular galectin-3 contributes to tissue fibrosis. 
Galectin-3 secreted by several cells, including 
monocytes and macrophages, can activate quiescent 
fibroblasts to myofibroblasts [26], which is the 
hallmark event in tissue fibrosis. Alternative 
macrophage activation (M2), implicated in tissue 
fibrosis also results in increased expression and 
secretion of galectin-3, and a positive feedback loop 
involving extracellular galectin-3 is thought to be 
responsible for sustained M2 activation of 
macrophages [46]. Galectin-3 could also promote 
fibrosis by modulating immuno-inflammatory 
responses and angiogenesis [72,73]. Furthermore, 
galectin-3 is hypothesized to form lectin-saccharide 
lattices on cell surfaces and transforming growth 
factor- ß (TGF-ß) receptor entrapment within the 
lattices could amplify profibrotic signalling [74].  
Galectin-3 modulates TGF-ß function and also 
appears to be a crucial regulator of pulmonary fibrosis 
by activating macrophages and fibroblasts. Both 
genetic inhibition and treatment with galectin-3 
inhibitor TD-139 reduced TGF-ß-induced and 
bleomycin-induced pulmonary fibrosis by reducing 
myofibroblast activation and collagen secretion [75]. 
In a hepatic fibrosis model, galectin-3 was required 
for TGF-ß-mediated myofibroblast activation and 
matrix production, and galectin-3 inhibition through 
in vivo siRNA knockdown prevented myofibroblast 
activation and hepatic injury [25]. In another model, 
disruption of galectin-3 gene resulted in reduced 
hepatic fibrosis although TGF-ß expression levels 
were not affected, suggesting that TGF-ß-mediated 
myofibroblast production and subsequent hepatic 
fibrosis required galectin-3, and galectin-3 could 
cause “TGF-ß-independent fibrosis” under certain 
circumstances (Figure 3) [25,76].  
Galectin-3 secretion from macrophages appears 
to be a main driver of renal fibrosis in animal models 
of kidney injury [26,77]. In a unilateral ureteral 
obstruction (UUO) model, galectin-3 KO mice 
developed reduced interstitial fibrosis compared to 
sham-operated WT mice: staining of kidney tissue 
using picrosirius red displayed increased 
collagen-deposition in WT mice with UUO compared 





to galectin-3 KO counterparts, and 
immunohistological staining for α-SMA was 
markedly reduced in galectin-3-KO mice [26]. In 
chronic allograft injury models, there was also a 
marked reduction of renal interstitial fibrosis 
(reduced collagen I and α-SMA) in galectin-3 KO mice 
compared to WT mice: although the number of 
infiltrating leukocytes in the renal tissue were 
comparable between WT and KO mice, alternative 
macrophage (M2) activation and CD4+ T cells were 
significantly reduced in galectin-3 KO mice 
suggesting that galectin-3 may promote M2 
macrophage activation and renal fibrosis 
post-transplantation [78]. The study conducted by 
Frenay and colleagues on REN2 rats added further 
evidence to the macrophage-galectin-3-fibrosis axis, 
and also highlighted the potential of pharmacological 
galectin-3 inhibition in ameliorating fibrosis: 
compared to untreated controls, inhibition of 
galectin-3 with N-acetyllactosamine (LacNAc) 
attenuated proteinuria, improved kidney function 
and reduced renal damage by significantly reducing 
macrophage infiltration, galectin-3 expression and 
α-SMA expression in this hypertensive nephropathy / 
HF model [79]. 
Cardiac Fibrosis and Heart Failure 
Several studies performed in the last decade in 
healthy population as well as in HF patients 
demonstrate the close relationship between galectin-3, 
cardiac fibrosis and HF [80–84]. Galectin-3 has a class 
II recommendation in HF management according to 
ACCF/AHA 2013 guidelines [85]. Furthermore, it is 
an emerging target in the treatment of cardiac fibrosis 
and HF [86], and in the following sections we 
summarize the role of galectin-3 as a biotarget. 
Animal Models of Cardiac Injury 
In a pioneering study, Sharma et al. observed 
that some hypertensive rats that overexpressed 
murine renin gene (REN-2 rats) developed overt HF 
after about 4 months, while others did not 
decompensate. Analysis of decompensated hearts 
revealed that galectin-3 was the strongest upregulated 
gene and its expression was about 5x higher 
compared to compensated hearts. Causality was 
tested by infusion of galectin-3 in pericardial sacs of 
normal rats; this resulted in increased collagen I/III 
ratio and also led to cardiac remodelling and 
dysfunction [23]. Following studies by Liu et al. also 
yielded similar results: galectin-3 infusion into 
pericardial sac resulted in inflammation, ventricular 
remodelling and cardiac dysfunction in male adult 
rats [87]. Conclusive evidence for the role of galectin-3 
in cardiac remodelling and fibrosis was accrued in the 
study conducted by Yu and colleagues [24]. Cardiac 
remodelling in mice was induced pharmacologically 
using angiotensin II infusion, or surgically through 
transverse aortic constriction (TAC); although 
galectin-3 KO mice developed left ventricular (LV) 
hypertrophy, they displayed no LV dysfunction and 
fibrosis. Pharmacological inhibition of galectin-3 with 
LacNAc also attenuated LV dysfunction and fibrosis 
in WT mice. On the other hand, untreated WT mice 
developed LV hypertrophy, fibrosis and adverse 
remodelling, highlighting that galectin-3 was not only 
a culprit protein but also a potential therapeutic target 
to counteract adverse cardiac remodelling.  
Other models of HF are also useful to further 
understand galectin-3-mediated mechanisms of 
cardiac dysfunction. In a murine angiotensin 
II-induced hypertension model, genetic deletion of 
galectin-3 reduced cardiac inflammation (decreased 
macrophage infiltration) and fibrosis while WT mice 
exhibited severe myocardial fibrosis. However, 
myocyte cross-sectional area, an indicator of cardiac 
hypertrophy, was significantly increased in both WT 
and galectin-3 KO groups suggesting that angiotensin 
II induced cardiac hypertrophy in both groups, but 
reduced fibrosis only in galectin-3 KO groups. LV 
function was also well preserved in galectin-3 KO 
mice while WT mice exhibited a decline in LV systolic 
function (ejection fraction, EF reduced from 84% ± 1% 
to 61% ± 3% and systolic function reduced from 71% ± 
0.3% to 57% ± 2%) [88]. Some reports suggest that 
galectin-3 could also be associated with cardiac injury 
and fibrosis in a non-hypertensive setting: when WT 
and galectin-3 KO mice were treated with aldosterone 
(1 mg/kg/day using osmotic minipump) for 3 weeks, 
galectin-3 KO mice displayed virtually no cardiac 
fibrosis. Similar effects were also elicited when 
aldosterone exposed WT mice were treated with a 
galectin-3 inhibitor, modified citrus pectin (MCP) [89]. 
Recently, in a canine model of HF with 
preserved ejection fraction (HFpEF) induced by aortic 
banding, myocardial galectin-3 was significantly 
upregulated after two weeks. Increase in galectin-3 
expression positively correlated to the severity of 
diastolic dysfunction assessed with the 
echocardiographic diastolic parameter – early 
transmitral flow velocity to early diastolic tissue 
velocity (E/Em) ratio [90]. Although it is evident that 
galectin-3 plays a crucial role in cardiac fibrosis and in 
HF, some studies have demonstrated the significance 
of galectin-3 in maintaining the integrity of cardiac 
tissue after necrosis. In a mouse model of myocardial 
infarction (MI), galectin-3 KO displayed an increased 
trend towards mortality, chiefly due to ventricular 
rupture [48], emphasizing that galectin-3 is necessary 
for normal wound healing, especially during the 





initial phases of cardiac repair.  
In vitro studies 
Cardiac fibroblasts exposed to recombinant 
galectin-3 resulted in proliferation, differentiation and 
increased production of collagen; this was blocked by 
galectin-3 knockdown [91]. Recent studies suggest 
that transmembrane proteoglycans such as syndecans 
are also involved in cardiac fibrosis: syndecans have 
several heparan sulphate GAG chains that could 
potentially interact with galectin-3 and affect 
profibrotic syndecan signalling in cardiac fibroblasts 
(Figure 3) [92,93].  
Although not directly involved in collagen 
production, M2 macrophages have an important role 
in collagen turnover affecting wound remodelling, 
and increased galectin-3 expression in activated 
macrophages has been observed in several in vitro 
studies [26,46,94–96]. Furthermore, galectin-3 also 
co-localized with activated macrophages in 
myocardial biopsies from failure-prone rats, 
suggesting that macrophage-derived galectin-3 could 
be an important player in cardiac remodelling [23]. 
Current studies indicate that galectin-3 can also 
be secreted by cardiomyocytes: mechanical stretching 
of cardiomyocytes in a cellular model of HFpEF 
resulted in increased galectin-3 expression in these 
cells, and also a significant increase in galectin-3 
secretion [90]. In a different study investigating effects 
of protein kinase C (PKC) in cardiac hypertrophy, 
exposure of rat cardiomyocytes (HL-1 cells) to the 
PKC activator, phorbol dibutyrate (PDBu), resulted in 
hypertrophy and increased galectin-3 protein 
expression and collagen production [97]; pretreatment 
of HL-1 cells with galectin-3 inhibitor (β-lactose) 
blocked collagen production, indicating that 
galectin-3 expression and collagen secretion may be 
closely associated in cardiomyocytes.  
In conclusion, although galectin-3 is a fibrogenic 
protein necessary for normal healing, sustained 
expression and secretion of galectin-3 within the 
cardiac tissue leads to adverse cardiac remodelling 
resulting in progressive fibrosis and HF. Genetic and 
pharmacological inhibition of galectin-3 reduces 
cardiac fibrosis in several animal models, and specific 
inhibitors that target galectin-3 mediated fibrosis 
appear to be quite promising in HF management. 
Atherosclerosis and Diabetes Mellitus 
type 2 
Atherosclerosis is a major cause of 
cardiovascular disease and galectin-3 levels are 
generally increased in atherosclerotic lesions. Foam 
cells, which are fat-laden macrophages, are 
abundantly present within atherosclerotic lesions and 
actively secrete galectin-3 [21]. This local increase in 
galectin-3 concentration could potentially be 
responsible for enhanced recruitment of monocytes 
and macrophages to the artery wall [65], exacerbating 
the pro-inflammatory state in atherosclerotic lesions 
[98]. However, galectin-3 might also contribute to 
pathogenesis through other mechanisms [99], 
including amplification of inflammatory pathways by 
intracellular mechanisms in macrophages [100]. Both 
genetic and pharmacological inhibition of galectin-3 
resulted in reduced atherosclerotic lesions and slowed 
atherosclerotic plaque-progression in apolipoprotein 
E-KO mice [101,102].  
The role of galectin-3 in DM type 2 is ambiguous: 
some studies claim that galectin-3 deficiency is 
associated with insulin resistance, and galectin-3 
elicits a protective effect in DM type 2 by acting as a 
receptor for advanced glycation end products (AGEs) 
[103,104]. However, a very recent study demonstrated 
that knocking out galectin-3 gene in mice fed with a 
high-fat diet significantly reduced the development of 
insulin resistance. Furthermore, this study also 
provides preliminary evidence that extracellular 
galectin-3 binds the insulin receptor directly and 
attenuates downstream pathways, suggesting 
galectin-3 to be a novel targetable link in insulin 
resistance and DM type 2 [105]. 
 Galectin-3 Activation 
Monomeric galectin-3 undergoes further 
physicochemical modifications that increase its range 
of biological functionality, especially extracellular 
activity. The most important mechanisms leading to 
“bio-activation” of galectin-3 are self-associations 
(multimerization) and formation of galectin-3 lattices.  
Self-associations of Galectin-3 
Self-association increases the spectrum of 
biological activity of galectin-3, and can be divided 
into intra-molecular associations, within one 
galectin-3 molecule, and intermolecular associations, 
between different galectin-3 molecules. Galectin-3 
self-association usually depends upon protein 
concentration and interaction with binding partners 
(ligands). Before delving into bio-activation of 
galectin-3 by such mechanisms, it is imperative to 
develop a general understanding of its structure and 
binding sites.  
Galectin-3 Structure: A Binding Perspective 
Galectin-3 molecule has a globular head with a 
diameter of about 3-4 nm attached to a slender 45-50 
nm long tail that has great conformational flexibility 
[106]. The globular head harbours the carbohydrate 
recognition domain (CRD); the long tail contains the 





collagenase cleavable H-domain and culminates as 
the amino N-terminal (NT). Although some authors 
prefer to use “collagen-like” domain, galectin-3 does 
not have the Gly-X-Y characteristic of collagens. 
From a chemical point of view, CRD is divided 
into five subsites (A-E): subsites C and D are 
responsible for binding ß-galactosides and the other 
subsites A, B and E are poorly characterized [107]. The 
CRD binds carbohydrate ligands, plays a role in 
C-type self-interactions [108] and is usually 
responsible for interactions occurring in the 
extracellular milieu [8,13]. The CRD is also known to 
interact with protein ligands such as β-catenin [38]. 
Galectin-3-functions are also modulated by the NT 
through various mechanisms including 
phosphorylation and self-interactions involving the 
NT region, e.g., NT-NT interactions and NT-CRD 
interactions [106,109]. Although the amino-terminal 
interacts with many ligands, it displays no 
carbohydrate-binding activity. The H-domain is the 
site of action of matrix metalloproteinases (MMPs) 
such as MMP 9 and MMP 2, and other proteases 
resulting in galectin-3 cleavage [110].  
The classical ß-galactoside-binding region of 
galectin-3 CRD, called the canonical binding site or 
S-face, binds saccharides such as lactose. The other 
frequently described site is the non-canonical sugar 
binding site, also called the F-face [111]. The 
non-canonical site is reported to bind “sugars” with a 
larger carbohydrate foot-print such as MCPs and 
galactomannans (GMs) (Figure 4). These two different 
carbohydrate binding sites are not mutually “ligand” 
exclusive: this implies that binding of a ligand to the 
canonical site does not exclude the binding of a ligand 
to the non-canonical F site and vice versa [108,112]. 
However, data suggest that ligand-binding to the 
canonical site weakens the affinity of a ligand to the 
non-canonical site and conversely, binding of a ligand 
to the non-canonical site weakens ligand affinity to 
the canonical-site [111].  
Galectin-3 Self-interactions: Role in Activation  
Galectin-3 self-interactions can be classified into 
intra-molecular interactions involving NT-CRD 
interactions and intermolecular interactions involving 
NT-NT and CRD-CRD interactions, and are usually 
modulated by various ligands [108,113]. 
Intra-molecular interactions lead to a relatively 
biologically inert galectin-3 molecule and 
intermolecular interactions result in bio-activation of 
galectin-3 by the formation of multimers.  
NT-CRD interactions 
Recent studies provide experimental evidence 
on intra-molecular interactions of galectin-3 resulting 
in a “closed conformer” and an “open conformer”. In 
the closed conformer, 
intra-molecular interactions 
occur between NT and F-face of 
the galectin-3 CRD resulting in 
stabilization of the molecule, 
rendering it relatively inert 
[114]: the NT effectively shields 
the CRD F-face in the closed 
conformation and could potenti-
ally block various interactions 
occurring in the non-canonical 
carbohydrate binding site. The 
canonical site is, however, open 
for interaction with classic 
ß-galactoside ligands such as 
lactose [115]. The liberation of 
NT from the CRD results in 
“opening-up” of (CRD) F-face to 
various binding partners. This 
“open conformer” also appears 
to be a prerequisite for 
intermolecular associations of 
galectin-3 resulting in dimeriza-
tion and oligomerization (Figure 
5).  
High resolution nuclear 
magnetic resonance (NMR) 
 
 
Figure 4: A simplified depiction of galectin-3 structure indicating the carbohydrate recognition domain (CRD), 
H-domain and the amino-terminal (N-terminal). The CRD is globular and consists of several carbohydrate 
binding-grooves. The most frequently described carbohydrate-binding sites are the canonical S-face and the 
non-canonical F-face. S-face binds β-galactosides such as lactose, while larger carbohydrates such as MCPs and 
GMs are reported to bind to the F-face. The CRD continues as a long and slender tail which ends in the 
N-terminal; the N-terminal does not exhibit carbohydrate-binding activity. CRD: carbohydrate recognition 
domain; N-terminal: amino terminal; MCP: modified citrus pectin; GM: galactomannan 





studies showed that there are significant 
intra-molecular interactions between N-terminal 
domain and CRD. This was based on reduction in 
movement of NT and shielding of nuclei in intact 
hamster galectin-3 molecule [106]. A previous 
modelling study done by Barboni et al. proposed two 
different models for NT-CRD intra-molecular 
interactions [116]. Recently, Halimi et al. also 
demonstrated the interactions between NT and CRD 
of human galectin-3 using NMR [109]. Further 
evidence for NT-CRD association was obtained from 
the study conducted by Berbis et al: they worked on 
peptides derived from human galectin-3 N-terminal 
and their interactions with galectin-3 CRD, and 
elegantly demonstrated the role of N-terminal 
phosphorylation in NT-CRD interactions. 
Phosphorylation of N-terminal peptides elicited 
resonance shifts in that part of the lectin that was 
opposite to the canonical ß-galactoside binding site, 
providing preliminary proof that NT interacts with 
the non-canonical CRD binding site (NT-CRD F-face 
interaction). It was also demonstrated that the 
canonical ß-galactoside binding site was left open for 
interaction with sugars such as lactose [115]. 
NT-CRD interactions could have functional 
consequences for galectin-3 CRD interactions. 
Ochieng et al. observed that cleaved galectin-3 CRD 
terminal binds laminin more tightly [117], suggesting 
a regulatory role of the N-terminal in 
CRD-glycoconjugate interactions. However, it is still 
to be elucidated if it is the open N-tail (open- 
conformer) that is responsible for this regulatory role 
or if it is the NT-CRD F-face interaction (closed- 
conformer) that contributes to such an effect. 
NT-NT interactions 
Early evidence for NT-NT interactions was 
obtained from experiments utilizing monoclonal 
antibodies to target the amino region of the intact 
galectin-3 molecule: binding of antibodies to NT 
modulated the lectin activities of galectin-3. Certain 
antibodies such as MAb B2C10 inhibited 
galectin-3-IgE interaction, galectin-3-induced 
hemagglutination activity and also galectin-3- 
mediated superoxide production by human 
neutrophils, while other antibodies such as MAb 
A3A12 potentiated these activities. Facilitation or 
inhibition of dimerization (oligomerization) by the NT 
or direct self-association of galectin-3 via the amino 
terminal was held responsible for such effects [118]. 
 
FIGURE 5: In this illustration, we depict the role of self-interactions in galectin-3 bioactivation. Intramolecular interactions between the carbohydrate recognition 
domain (CRD) and the N-terminal render the galectin-3 molecule relatively inert in the closed conformer state; the galectin-3 molecule can still bind S-face ligands 
such as lactose in this state. Release of the N-terminal from the F-face results in the open conformer which is biologically more active. The open conformer can bind 
to various ligands (both S-face ligands and F-face ligands) and can also undergo dimerization or oligomerization. Two types of intermolecular interactions, N-terminal 
interactions and CRD-CRD interactions, are usually observed during multimerization and this results in increased biological activity of galectin-3. CRD: carbohydrate 
recognition domain 





Electron microscopy of NT fragments showed 
that their structure was fibrillar. Two types of 
N-terminal interactions were observed: side-side 
associations with “thickening” of fibrils suggesting 
oligomerization, and head-to-tail interactions 
resulting in considerable variation in fibril length 
[106]. Direct analysis of galectin-3 self-association 
using a solid-phase radioligand binding assay 
revealed that homophilic interactions of galectin-3 are 
mediated by the CRD in addition to the amino 
terminal. Moreover, these homophilic interactions 
could be potentiated by asialofetuin (ASF), which is a 
multivalent glycoprotein, and inhibited by lactose 
[119].  
The existence of galectin-3 as a pentamer formed 
by N-terminal association has been described in the 
seminal paper by Ahmad et al. They also reported 
that galectin-3 shuttles rapidly between the 
monomeric and pentameric forms (equilibrium state) 
and precipitates as a pentamer with a series of 
divalent pentasaccharides with terminal LacNac 
residues [113]. A monomer-pentamer model thus 
emerged and several articles have adopted the 
N-terminal pentameric form as the classical (and only) 
form of oligomerization. Further experimental 
evidence for NT-NT oligomerization in the biological 
setting was accumulated by Fermino et al. Fluorescein 
isothiocyanate (FITC)-labelled full length galectin-3, 
unlike truncated galectin-3 (Gal-3C), exhibited a 
non-saturable binding to neutrophils and enhanced 
neutrophil activation, indicating that galectin-3 
oligomerization induced by its interaction with 
lipopolysaccharide (LPS) was mediated by N-terminal 
during neutrophil activation [120]. 
Evidence for galectin-3 self-association utilizing 
NT-NT interactions induced by the CRD-ligand LNnT 
(lacto-N-neoTetraose) was accrued by Halimi and 
colleagues [109]. Pentamers and oligomers were 
observed using dynamic light scattering (DLS), and 
LNnT induced such effects only in full length protein, 
but not in recombinant CRD: LNnT, a neo-glycan, 
associates with galectin-3-CRD and probably releases 
the N-terminal domain from the CRD-F face, 
facilitating the formation of the “open” from of 
galectin-3. The free N-terminals in the “open 
conformer” could then interact with each other and 
form multimers through NT-NT interactions.  
Although in many of the above-mentioned 
experiments, NT self-interactions required (CRD) 
ligands, a very recent NMR-based study evaluating 
the intrinsic propensity of (human) galectin-3 to 
self-associate reported that NT-NT interactions could 
also occur in a ligand-independent, concentration- 
dependent manner, through fuzzy interactions [121]. 
An earlier NMR study performed by Ippel et al. on 
(human) galectin-3 did not observe such NT-NT 
interactions, but concluded that intermolecular 
interactions occurred between F-faces of CRD, and NT 
facilitated such interactions [114].  
CRD-CRD interactions 
It has been generally accepted that NT is 
responsible for galectin-3 oligomerization, and 
ligand-binding to CRD could potentiate this effect. 
However, several studies including a recent study by 
Lepur et al. indicate that direct CRD-CRD interactions 
can also lead to galectin-3 oligomerization.  
Yang et al. demonstrated, for the first time, 
self-association of galectin-3 utilizing CRD in the 
absence of saccharide ligands [122]. Further evidence 
for CRD-CRD interactions was accrued from the 
study conducted by Birdsall et al. in which intact 
hamster galectin-3 and also the CRD fragments were 
visualized in monomeric, dimeric and trimeric forms 
using electron microscopy [106]. A recent study by 
Lepur et al. using fluorescence anisotropy assay 
demonstrates the role of ASF (ligand / nucleating 
agent) in inducing galectin-3 multimerization through 
its CRD, and this has been named as C-type 
association. Efficient C-type oligomerization was not 
observed in solution previously and this would be the 
first study to describe such an effect. A monovalent or 
divalent LacNAc containing glycan was able to 
induce this C-type association, emphasizing that for 
efficient C-type self-association, a step of initiation or 
nucleation is necessary [108]. Precipitation also 
occurred with a divalent LacNAc containing ligand at 
very high concentrations (>50 µM) and this could be 
due to N-type association.  
Thus, it appears that galectin-3 self-aggregation 
occurs either due to NT-NT interactions, [106,113] 
CRD-CRD interactions [108,109] or a mixture of both 
depending on galectin-3 concentration and 
availability of ligands and nucleating agents.  
Galectin-3 Lattice: A Higher Level of 
Activation 
Although galectin-3 can influence a variety of 
biological processes through self-interactions, a 
higher level of biological functionality is achieved 
through the formation of three dimensional 
frameworks consisting of galectin-3 in its different 
forms and several types of saccharide ligands [68]. 
This multi-dimensional organization, together with 
other components of the cell surface, is usually 
referred to as the cell surface “galectin-glycoprotein 
lattice” [123] (Figure 6). As self-interaction(s) of 
galectin-3 and also surface expression of glycosylated 
proteins and lipids keep changing continuously, this 
lattice is envisioned to be a highly dynamic structure 





similar to the cell membrane, and it has been 
described as an additional layer of membrane 
organization on extracellular surfaces of cell 
membranes [74]. The lattice formed by galectin-3 is 
also perceived to be stable, and the stability of these 
lattices at the surface of endothelial cells was visually 
demonstrated by Nieminen and colleagues while 
studying galectin-3 oligomerization; stability of 
galectin-3 lattice was further tested using fluorescence 
recovery after photobleaching (FRAP) technique 
[123].  
Galectin-3 self-association and its interaction 
with various surface glycoproteins and glycolipids are 
important in the formation and maintenance of the 
lattice structure, and also in the regulation and 
distribution of glycoproteins at the cell-surface [74]. 
For cross-linking by galectin-3, glycoproteins and 
glycolipids should have appropriate glycosylation 
patterns. For instance, if the end terminal is sialic acid, 
the formation of a cross-linked lattice is disrupted 
[68]. Affinity of N-glycans for galectins in this lattice 
also increases with branching and 
poly-N-acetyllactosamine extensions. Uridine 
diphosphate-N-acetylglucosamine (UDP-GlcNac) is 
essential for these processes, and as glucose, 
glutamine and acetyl-CoA are necessary for the 
biosynthesis of UDP-GlcNAc, and N-glycan 
branching is dependent on UDP-GlcNac, such factors 
could potentially regulate glycoprotein retention in 
the lattice [124]. Receptors with five or more 
glycosylated sites are largely associated within the 
lattice [125]. 
Galectin lattice acts as a physical barrier and a 
biological sensor by regulating the entry of various 
pathogens by constantly surveying the extracellular 
milieu. It also associates with various receptor kinases 
(which are usually glycosylated) to bring about 
changes in intracellular biological processes [125]. 
Moreover, galectin lattice could potentially regulate 
metabolic homeostasis by changing the number and 
activity of cell surface receptors such as glucagon 
receptors and solute transporters [124]. It is also 
speculated to critically regulate T-cell receptor 
sensitivity, which can have a crucial role in the 
development of autoimmune diseases and cancer 
[67,69]. Galectin-3 lattice could also have a role in 
TGF-ß receptor entrapment, especially those receptors 
with N-linked glycosylation patterns [126] and this 
could possibly amplify TGF-ß mediated profibrotic 
signalling [125]. Thus galectin-3 through its 
self-associating, lattice-forming behaviour could 
influence innumerable biological processes, many of 
which still remain to be elucidated.  
 
FIGURE 6: Galectin-3 lattices are focal, three-dimensional frameworks consisting of galectin-3 in its different forms and multimerization states, and is envisioned to 
be an additional layer of membrane organization. Galectin-3 interacts with various binding partners, usually carbohydrate molecules that project from glycoproteins 
and glycolipids, regulating several important biological processes. Galectin-3 lattices are a part of the larger “lectin-saccharide” lattices. 






As the carbohydrate recognition region of 
(extracellular) galectin-3 is responsible for several 
pathological effects orchestrated by this protein, 
pharmacological inhibition of galectin-3 has almost 
exclusively targeted the CRD for inhibiting 
(extracellular) activities of this protein. The CRD can 
be inhibited using carbohydrates that compete for the 
binding site or allosterically modulate it so as to 
render the CRD incapable of binding to ligands. Steric 
hindrance offered by high-molecular-weight 
compounds has also been exploited to confer 
additional galectin-3 inhibiting properties. 
Heparin-based inhibitors, truncated galectin-3 and 
peptide inhibitor G3-C12 have only been evaluated in 
cancer setting; however, we also discuss them briefly 
as they could evolve as promising candidates in the 
therapy of organ fibrosis and HF.  
Carbohydrate-based compounds 
Simple Sugars 
Pharmacological inhibition of galectin-3 with 
LacNAc prevented LV dysfunction in failure-prone 
REN2 rats [24] and also had a protective effect against 
hypertensive nephropathy in REN2 rats [79]. 
Low-molecular-weight sugars such as lactose or 
LacNAc, however, cannot be used as “drugs” as they 
are rapidly absorbed and metabolized.  
Galactomannans and Modified Citrus Pectin  
GMs are galectin antagonists derived from 
plants. GM-CT-01, known by its trade name 
Davanat® is a GM (MW ~50kDa) with a half-life 
between 12 h and 18 h [128]. The safety profile of 
GM-CT-01 has been established, and half-life of 
Davanat® is much higher than that of LacNAc, 
making it more suitable for clinical use. Experimental 
evidence from Demotte et al. demonstrates that 
Davanat® is able to improve the activity of human 
tumour infiltrating lymphocytes, and disrupts 
galectin-glycoprotein lattices [127,128]; however, the 
exact mechanism of action remains unclear. In 
another study by Traber et al., two complex 
carbohydrate anti-galectin-3 drugs (GM-CT-01 and 
GR-MD-02) were used to treat nonalcoholic 
steatohepatitis (NASH) and fibrosis in a murine 
model. GM-CT-01 is a GM polysaccharide while 
GR-MD-02 is a galactoarabinorhamnogalacturonan 
polysaccharide polymer; GR-MD-02 performed better 
than GM-CT-01 in reducing hepatocellular damage, 
inflammation and fibrosis in the experimental NASH 
mouse model and both drugs reduced galectin-3 
expression in macrophages [129]. 
Different types of MCPs (MW > 1000 kDa), e.g., 
GCS-100 and PectaSol-C®, are available commercially 
and several experiments performed in the past years 
successfully employ MCPs for targeting fibrosis. The 
galectin-3 inhibitory effects of MCPs have been 
investigated in various cellular and animal models: 
these include inhibition of galectin-3-mediated 
hemagglutination, reduction of cardiac inflammation, 
attenuation of organ fibrosis and reduction of 
atherosclerosis in apolipoprotein E-deficient mice 
[70,89,101,130–134]. Furthermore, MCPs have an 
acceptable human safety profile [134] and have been 
evaluated as cancer therapeutic agents [127]. 
Although not clearly established, it was assumed 
that inhibition of galectin-3 at the classical 
ß-galactoside binding site was responsible for 
anti-galectin-3 effects elicited by GMs and MCPs. 
However, a recent study by Miller et al. suggests that 
MCPs and polysaccharides with a larger carbohydrate 
foot print such as GMs bind to the non-canonical site 
in the CRD (F-face) instead of the canonical S-face 
[111]. This is also in line with the study conducted by 
Stegmayr et al. who demonstrated that the biological 
inhibitory effects of several different MCPs and GMs 
could not be due to inhibition of the canonical 
carbohydrate binding site [112]. If the established 
biological inhibitory effects of pectins and GMs can be 
conclusively attributed to the inhibition of the 
non-canonical binding site as suggested by Miller and 
colleagues, it would emerge as an attractive target for 
designing novel galectin-3 inhibitors.  
Several studies claim that GMs and MCPs inhibit 
hemagglutination mediated by galectin-3 [70,132,133]; 
however, Stegmayr and colleagues demonstrated for 
the first time that Davanat® and MCPs including 
Pectasol-C® did not block galectin-3-induced 
hemagglutination [112]. Compounds inhibiting 
hemagglutination could block galectin-3 activation by 
disrupting the lattice-forming behaviour of this 
protein, and hence it is necessary to carry out further 
studies to precisely understand the mode of action of 
antifibrotic MCPs and GMs. It should also be noted 
that in many in vivo studies, the specificity of MCPs 
was not established and the possibility that their 
inhibitory activity was due to effects on targets other 
than galectin-3 also needs to be addressed.  
Thiodigalactosides 
Recently, thiodigalactoside derivatives targeting 
novel CRD sites other than the canonical binding site 
have emerged. TD-139 is a thiodigalactoside analogue 
that has been approved by the USFDA for the 
treatment of idiopathic pulmonary fibrosis as an 
inhaled powder, and is speculated to antagonize 
galectin-3 by binding to subsites B and E [107]. It is a 
small molecule (C28H30F2N6O8S) with a molecular 





weight of approximately 648 g/mol and can bind with 
high affinity to both galectin-3 and galectin-1. 
Although the mechanism of action is unclear, it is 
possible that this molecule allosterically modulates 
galectin-3 CRD. Some research groups also 
demonstrate that thiodigalactosides could be 
preferentially “tuned” to create more specific 
galectin-3 inhibitors [135].  
Heparin-based inhibitors 
They are a relatively new and attractive group of 
galectin-3 inhibitors that are sulphated or acetylated 
derivatives of heparin. In vitro results demonstrated 
that they were non-cytotoxic and galectin-3 selective 
(i.e., did not inhibit galectin-1, -4 and -8), and in in vivo 
experiments with nude mice these compounds 
significantly reduced galectin-3-mediated lung 
metastasis of human melanoma and colon cancer 
cells. Furthermore, these compounds exhibited no 
detectable anticoagulant activity, and appear to be 
promising therapeutic agents [136]. However, they 
have been tested only in in vivo models of metastasis 
and future studies need to be conducted to evaluate 
their potential as antifibrotic agents.  
Neoglycoconjugates  
Galectin-3 binds to branched-chain sugars with 
increased avidity and large lactose functionalized 
dendrimers provide an “excess of ligands” for 
galectin-3 binding. Michel and colleagues studied the 
effects of different types of lactose-functionalized 
dendrimers on cancer-cell aggregation and found that 
smaller dendrimers inhibited homotypic cellular 
aggregation, probably through competitive inhibition, 
while larger dendrimers with several lactose end 
groups enhanced aggregation by providing multiple 
galectin-3 binding sites [137]. Other chemically 
engineered glycoproteins (neoglycoproteins) have 
also been developed recently and have the potential to 
be used as novel therapeutic molecules against 
fibrosis by effectively targeting galectin-3. They not 
only serve as high affinity ligands but can also be 
modulated to achieve selectivity to galectin-3 over 
other galectins. Their use in the clinical setting is yet 
to be evaluated [138]. 
Peptide-based Compounds  
NH2 terminally truncated galectin-3 (Gal-3C) 
has been evaluated in the therapy of galectin-3 
related-tumours and it appears to be a promising 
agent with a low-toxicity profile [139–141]. However, 
there are no studies evaluating its potential in treating 
other galectin-3 related pathologies.  
Recently, Sun and colleagues utilized galectin-3 
binding peptide, G3-C12 to inhibit intracellular 
galectin-3 in cancer cells. As G3-C12 has a high 
selectivity to galectin-3 over other galectins, it 
functions as a selective galectin-3 targeting ligand. 
When this peptide is conjugated to a drug using a 
versatile drug carrier such as N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer, the resulting 
G3-C12-HPMA-drug conjugate could easily 
internalize into galectin-3 overexpressing cells [142]. 
This galectin-3 selective intracellular delivery concept 
could possibly also find utility in other 
galectin-3-related disease scenarios such as organ 
fibrosis and HF. 
Conclusion 
Activation of monomeric galectin-3 increases the 
spectrum of biological activity of this pleiotropic 
protein in various physiological and patho- 
physiological processes. It is however essential to 
understand that there could be more components to 
galectin-3 activation. It remains unclear how 
galectin-3 function might be modulated by other 
galectin members, signalling molecules such as 
syndecans and other biologically active molecules. 
Current understanding of various binding partners of 
galectin-3 is also incomplete. Further characterization 
and visualization of the galectin-3 lattice utilizing 
advanced (optical) techniques is necessary to 
understand the exact mechanisms by which this 
regulatory protein influences various (extra)cellular 
processes.  
Although galectin-3 has been implicated in 
several debilitating disorders, only a few galectin-3 
inhibitors have been developed that are of clinical 
relevance. There is an urgent need to develop 
galectin-3 inhibitors that have a high oral 
bioavailability and a low toxicity profile to combat 
progressive tissue fibrosis and galectin-3-related HF. 
While treating such disorders, it is necessary to pay 
attention to the “window of opportunity” as 
overexpression of galectin-3 could be protective in 
certain scenarios, especially during initial stages of 
wound healing after injury, and galectin-3 inhibition 
during this phase may result in loss of tissue integrity. 
Finally, galectin-3 is a pleiotropic protein with several 
physiological functions, and galectin-3 blockade could 
also inhibit such functions resulting in off-target 
side-effects. Thus, the timing of treatment, eligibility 
of patients and their genetics must be carefully 
considered before initiating therapies with galectin-3 
inhibitors.  
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